DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q1 2026 vs. Q4 2025
How the institutions holding DBV Technologies S.A. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 52 | 71 | +19 |
| Shares | 16.2M | 21.2M | +5.00M (+30.9%) |
| Value | $302.1M | $433.6M | +$131.5M (+43.5%) |
New holders (29)
Institutions that held DBV Technologies S.A. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (10)
Institutions that held DBV Technologies S.A. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Schonfeld Strategic Advisors LLC | 454,343 | $8.71M |
| Vestal Point Capital, LP | 300,000 | $5.75M |
| Squadron Capital Management LLC | 240,000 | $4.60M |
| Citadel Advisors LLC | 145,129 | $2.78M |
| Two Sigma Investments, LP | 33,947 | $650.8K |
| Logos Global Management LP | 25,000 | $479.3K |
| Marshall Wace, LLP | 20,961 | $401.8K |
| HighVista Strategies LLC | 15,877 | $304.4K |
| Mark Sheptoff Financial Planning, LLC | 300 | $5.75K |
| Bank of America Corp | 257 | $4.93K |